Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
6,735
archived clinical trials in
Psoriasis

Study to Evaluate Safety and Effectiveness of Oral Apremilast (CC-10004) in Patients With Moderate to Severe Plaque Psoriasis
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Apremilast (CC-10004) in Subjects With Moderate to Severe Plaque Psoriasis
Status: Enrolling
Updated:  1/28/2016
International Dermatology Research, Inc.
mi
from
Miami, FL
Study to Evaluate Safety and Effectiveness of Oral Apremilast (CC-10004) in Patients With Moderate to Severe Plaque Psoriasis
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Apremilast (CC-10004) in Subjects With Moderate to Severe Plaque Psoriasis
Status: Enrolling
Updated: 1/28/2016
International Dermatology Research, Inc.
mi
from
Miami, FL
Click here to add this to my saved trials
Study to Evaluate Safety and Effectiveness of Oral Apremilast (CC-10004) in Patients With Moderate to Severe Plaque Psoriasis
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Apremilast (CC-10004) in Subjects With Moderate to Severe Plaque Psoriasis
Status: Enrolling
Updated:  1/28/2016
Renstar Medical Research
mi
from
Ocala, FL
Study to Evaluate Safety and Effectiveness of Oral Apremilast (CC-10004) in Patients With Moderate to Severe Plaque Psoriasis
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Apremilast (CC-10004) in Subjects With Moderate to Severe Plaque Psoriasis
Status: Enrolling
Updated: 1/28/2016
Renstar Medical Research
mi
from
Ocala, FL
Click here to add this to my saved trials
Study to Evaluate Safety and Effectiveness of Oral Apremilast (CC-10004) in Patients With Moderate to Severe Plaque Psoriasis
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Apremilast (CC-10004) in Subjects With Moderate to Severe Plaque Psoriasis
Status: Enrolling
Updated:  1/28/2016
Atlanta Dermatology, Vein & Research Ctr
mi
from
Alpharetta, GA
Study to Evaluate Safety and Effectiveness of Oral Apremilast (CC-10004) in Patients With Moderate to Severe Plaque Psoriasis
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Apremilast (CC-10004) in Subjects With Moderate to Severe Plaque Psoriasis
Status: Enrolling
Updated: 1/28/2016
Atlanta Dermatology, Vein & Research Ctr
mi
from
Alpharetta, GA
Click here to add this to my saved trials
Study to Evaluate Safety and Effectiveness of Oral Apremilast (CC-10004) in Patients With Moderate to Severe Plaque Psoriasis
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Apremilast (CC-10004) in Subjects With Moderate to Severe Plaque Psoriasis
Status: Enrolling
Updated:  1/28/2016
Gwinnett Clinical Research Center, Inc
mi
from
Snellville, GA
Study to Evaluate Safety and Effectiveness of Oral Apremilast (CC-10004) in Patients With Moderate to Severe Plaque Psoriasis
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Apremilast (CC-10004) in Subjects With Moderate to Severe Plaque Psoriasis
Status: Enrolling
Updated: 1/28/2016
Gwinnett Clinical Research Center, Inc
mi
from
Snellville, GA
Click here to add this to my saved trials
Study to Evaluate Safety and Effectiveness of Oral Apremilast (CC-10004) in Patients With Moderate to Severe Plaque Psoriasis
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Apremilast (CC-10004) in Subjects With Moderate to Severe Plaque Psoriasis
Status: Enrolling
Updated:  1/28/2016
Altman Dermatology Associates
mi
from
Arlington Heights, IL
Study to Evaluate Safety and Effectiveness of Oral Apremilast (CC-10004) in Patients With Moderate to Severe Plaque Psoriasis
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Apremilast (CC-10004) in Subjects With Moderate to Severe Plaque Psoriasis
Status: Enrolling
Updated: 1/28/2016
Altman Dermatology Associates
mi
from
Arlington Heights, IL
Click here to add this to my saved trials
Study to Evaluate Safety and Effectiveness of Oral Apremilast (CC-10004) in Patients With Moderate to Severe Plaque Psoriasis
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Apremilast (CC-10004) in Subjects With Moderate to Severe Plaque Psoriasis
Status: Enrolling
Updated:  1/28/2016
NorthShore University HealthSystem
mi
from
Skokie, IL
Study to Evaluate Safety and Effectiveness of Oral Apremilast (CC-10004) in Patients With Moderate to Severe Plaque Psoriasis
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Apremilast (CC-10004) in Subjects With Moderate to Severe Plaque Psoriasis
Status: Enrolling
Updated: 1/28/2016
NorthShore University HealthSystem
mi
from
Skokie, IL
Click here to add this to my saved trials
Study to Evaluate Safety and Effectiveness of Oral Apremilast (CC-10004) in Patients With Moderate to Severe Plaque Psoriasis
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Apremilast (CC-10004) in Subjects With Moderate to Severe Plaque Psoriasis
Status: Enrolling
Updated:  1/28/2016
Dundee Dermatology
mi
from
West Dundee, IL
Study to Evaluate Safety and Effectiveness of Oral Apremilast (CC-10004) in Patients With Moderate to Severe Plaque Psoriasis
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Apremilast (CC-10004) in Subjects With Moderate to Severe Plaque Psoriasis
Status: Enrolling
Updated: 1/28/2016
Dundee Dermatology
mi
from
West Dundee, IL
Click here to add this to my saved trials
Study to Evaluate Safety and Effectiveness of Oral Apremilast (CC-10004) in Patients With Moderate to Severe Plaque Psoriasis
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Apremilast (CC-10004) in Subjects With Moderate to Severe Plaque Psoriasis
Status: Enrolling
Updated:  1/28/2016
Dawes Fretzin Clinical Research Group, LLC
mi
from
Indianapolis, IN
Study to Evaluate Safety and Effectiveness of Oral Apremilast (CC-10004) in Patients With Moderate to Severe Plaque Psoriasis
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Apremilast (CC-10004) in Subjects With Moderate to Severe Plaque Psoriasis
Status: Enrolling
Updated: 1/28/2016
Dawes Fretzin Clinical Research Group, LLC
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Study to Evaluate Safety and Effectiveness of Oral Apremilast (CC-10004) in Patients With Moderate to Severe Plaque Psoriasis
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Apremilast (CC-10004) in Subjects With Moderate to Severe Plaque Psoriasis
Status: Enrolling
Updated:  1/28/2016
DermResearch, PLLC
mi
from
Louisville, KY
Study to Evaluate Safety and Effectiveness of Oral Apremilast (CC-10004) in Patients With Moderate to Severe Plaque Psoriasis
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Apremilast (CC-10004) in Subjects With Moderate to Severe Plaque Psoriasis
Status: Enrolling
Updated: 1/28/2016
DermResearch, PLLC
mi
from
Louisville, KY
Click here to add this to my saved trials
Study to Evaluate Safety and Effectiveness of Oral Apremilast (CC-10004) in Patients With Moderate to Severe Plaque Psoriasis
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Apremilast (CC-10004) in Subjects With Moderate to Severe Plaque Psoriasis
Status: Enrolling
Updated:  1/28/2016
Dermatology & Advanced Aesthetics
mi
from
Lake Charles, LA
Study to Evaluate Safety and Effectiveness of Oral Apremilast (CC-10004) in Patients With Moderate to Severe Plaque Psoriasis
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Apremilast (CC-10004) in Subjects With Moderate to Severe Plaque Psoriasis
Status: Enrolling
Updated: 1/28/2016
Dermatology & Advanced Aesthetics
mi
from
Lake Charles, LA
Click here to add this to my saved trials
Study to Evaluate Safety and Effectiveness of Oral Apremilast (CC-10004) in Patients With Moderate to Severe Plaque Psoriasis
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Apremilast (CC-10004) in Subjects With Moderate to Severe Plaque Psoriasis
Status: Enrolling
Updated:  1/28/2016
ORA Inc
mi
from
Andover, MA
Study to Evaluate Safety and Effectiveness of Oral Apremilast (CC-10004) in Patients With Moderate to Severe Plaque Psoriasis
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Apremilast (CC-10004) in Subjects With Moderate to Severe Plaque Psoriasis
Status: Enrolling
Updated: 1/28/2016
ORA Inc
mi
from
Andover, MA
Click here to add this to my saved trials
Study to Evaluate Safety and Effectiveness of Oral Apremilast (CC-10004) in Patients With Moderate to Severe Plaque Psoriasis
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Apremilast (CC-10004) in Subjects With Moderate to Severe Plaque Psoriasis
Status: Enrolling
Updated:  1/28/2016
Massachusetts General Women's Hospitals Harvard Medical School
mi
from
Boston, MA
Study to Evaluate Safety and Effectiveness of Oral Apremilast (CC-10004) in Patients With Moderate to Severe Plaque Psoriasis
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Apremilast (CC-10004) in Subjects With Moderate to Severe Plaque Psoriasis
Status: Enrolling
Updated: 1/28/2016
Massachusetts General Women's Hospitals Harvard Medical School
mi
from
Boston, MA
Click here to add this to my saved trials
Study to Evaluate Safety and Effectiveness of Oral Apremilast (CC-10004) in Patients With Moderate to Severe Plaque Psoriasis
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Apremilast (CC-10004) in Subjects With Moderate to Severe Plaque Psoriasis
Status: Enrolling
Updated:  1/28/2016
Clinical Pharmacology Study Group
mi
from
Worcester, MA
Study to Evaluate Safety and Effectiveness of Oral Apremilast (CC-10004) in Patients With Moderate to Severe Plaque Psoriasis
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Apremilast (CC-10004) in Subjects With Moderate to Severe Plaque Psoriasis
Status: Enrolling
Updated: 1/28/2016
Clinical Pharmacology Study Group
mi
from
Worcester, MA
Click here to add this to my saved trials
Study to Evaluate Safety and Effectiveness of Oral Apremilast (CC-10004) in Patients With Moderate to Severe Plaque Psoriasis
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Apremilast (CC-10004) in Subjects With Moderate to Severe Plaque Psoriasis
Status: Enrolling
Updated:  1/28/2016
Minnesota Clinical Study Center
mi
from
Fridley, MN
Study to Evaluate Safety and Effectiveness of Oral Apremilast (CC-10004) in Patients With Moderate to Severe Plaque Psoriasis
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Apremilast (CC-10004) in Subjects With Moderate to Severe Plaque Psoriasis
Status: Enrolling
Updated: 1/28/2016
Minnesota Clinical Study Center
mi
from
Fridley, MN
Click here to add this to my saved trials
Study to Evaluate Safety and Effectiveness of Oral Apremilast (CC-10004) in Patients With Moderate to Severe Plaque Psoriasis
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Apremilast (CC-10004) in Subjects With Moderate to Severe Plaque Psoriasis
Status: Enrolling
Updated:  1/28/2016
Central Dermatology
mi
from
St. Loius, MO
Study to Evaluate Safety and Effectiveness of Oral Apremilast (CC-10004) in Patients With Moderate to Severe Plaque Psoriasis
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Apremilast (CC-10004) in Subjects With Moderate to Severe Plaque Psoriasis
Status: Enrolling
Updated: 1/28/2016
Central Dermatology
mi
from
St. Loius, MO
Click here to add this to my saved trials
Study to Evaluate Safety and Effectiveness of Oral Apremilast (CC-10004) in Patients With Moderate to Severe Plaque Psoriasis
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Apremilast (CC-10004) in Subjects With Moderate to Severe Plaque Psoriasis
Status: Enrolling
Updated:  1/28/2016
Skin Specialists, PC
mi
from
Omaha, NE
Study to Evaluate Safety and Effectiveness of Oral Apremilast (CC-10004) in Patients With Moderate to Severe Plaque Psoriasis
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Apremilast (CC-10004) in Subjects With Moderate to Severe Plaque Psoriasis
Status: Enrolling
Updated: 1/28/2016
Skin Specialists, PC
mi
from
Omaha, NE
Click here to add this to my saved trials
Study to Evaluate Safety and Effectiveness of Oral Apremilast (CC-10004) in Patients With Moderate to Severe Plaque Psoriasis
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Apremilast (CC-10004) in Subjects With Moderate to Severe Plaque Psoriasis
Status: Enrolling
Updated:  1/28/2016
Psoriasis Treatment Center of Central New Jersey
mi
from
East Windsor, NJ
Study to Evaluate Safety and Effectiveness of Oral Apremilast (CC-10004) in Patients With Moderate to Severe Plaque Psoriasis
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Apremilast (CC-10004) in Subjects With Moderate to Severe Plaque Psoriasis
Status: Enrolling
Updated: 1/28/2016
Psoriasis Treatment Center of Central New Jersey
mi
from
East Windsor, NJ
Click here to add this to my saved trials
Study to Evaluate Safety and Effectiveness of Oral Apremilast (CC-10004) in Patients With Moderate to Severe Plaque Psoriasis
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Apremilast (CC-10004) in Subjects With Moderate to Severe Plaque Psoriasis
Status: Enrolling
Updated:  1/28/2016
UMDNJ-Robert Wood Johnson Medical School Clinical Research Center
mi
from
New Brunswick, NJ
Study to Evaluate Safety and Effectiveness of Oral Apremilast (CC-10004) in Patients With Moderate to Severe Plaque Psoriasis
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Apremilast (CC-10004) in Subjects With Moderate to Severe Plaque Psoriasis
Status: Enrolling
Updated: 1/28/2016
UMDNJ-Robert Wood Johnson Medical School Clinical Research Center
mi
from
New Brunswick, NJ
Click here to add this to my saved trials
Study to Evaluate Safety and Effectiveness of Oral Apremilast (CC-10004) in Patients With Moderate to Severe Plaque Psoriasis
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Apremilast (CC-10004) in Subjects With Moderate to Severe Plaque Psoriasis
Status: Enrolling
Updated:  1/28/2016
NYU Langone Medical Center
mi
from
New York, NY
Study to Evaluate Safety and Effectiveness of Oral Apremilast (CC-10004) in Patients With Moderate to Severe Plaque Psoriasis
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Apremilast (CC-10004) in Subjects With Moderate to Severe Plaque Psoriasis
Status: Enrolling
Updated: 1/28/2016
NYU Langone Medical Center
mi
from
New York, NY
Click here to add this to my saved trials
Study to Evaluate Safety and Effectiveness of Oral Apremilast (CC-10004) in Patients With Moderate to Severe Plaque Psoriasis
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Apremilast (CC-10004) in Subjects With Moderate to Severe Plaque Psoriasis
Status: Enrolling
Updated:  1/28/2016
Icahn School of Medicine at Mount Sinai
mi
from
New York, NY
Study to Evaluate Safety and Effectiveness of Oral Apremilast (CC-10004) in Patients With Moderate to Severe Plaque Psoriasis
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Apremilast (CC-10004) in Subjects With Moderate to Severe Plaque Psoriasis
Status: Enrolling
Updated: 1/28/2016
Icahn School of Medicine at Mount Sinai
mi
from
New York, NY
Click here to add this to my saved trials
Study to Evaluate Safety and Effectiveness of Oral Apremilast (CC-10004) in Patients With Moderate to Severe Plaque Psoriasis
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Apremilast (CC-10004) in Subjects With Moderate to Severe Plaque Psoriasis
Status: Enrolling
Updated:  1/28/2016
DermResearchCenter of New York, Inc
mi
from
Stony Brook, NY
Study to Evaluate Safety and Effectiveness of Oral Apremilast (CC-10004) in Patients With Moderate to Severe Plaque Psoriasis
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Apremilast (CC-10004) in Subjects With Moderate to Severe Plaque Psoriasis
Status: Enrolling
Updated: 1/28/2016
DermResearchCenter of New York, Inc
mi
from
Stony Brook, NY
Click here to add this to my saved trials
Study to Evaluate Safety and Effectiveness of Oral Apremilast (CC-10004) in Patients With Moderate to Severe Plaque Psoriasis
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Apremilast (CC-10004) in Subjects With Moderate to Severe Plaque Psoriasis
Status: Enrolling
Updated:  1/28/2016
University Hospitals of Cleveland
mi
from
Cleveland, OH
Study to Evaluate Safety and Effectiveness of Oral Apremilast (CC-10004) in Patients With Moderate to Severe Plaque Psoriasis
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Apremilast (CC-10004) in Subjects With Moderate to Severe Plaque Psoriasis
Status: Enrolling
Updated: 1/28/2016
University Hospitals of Cleveland
mi
from
Cleveland, OH
Click here to add this to my saved trials
Study to Evaluate Safety and Effectiveness of Oral Apremilast (CC-10004) in Patients With Moderate to Severe Plaque Psoriasis
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Apremilast (CC-10004) in Subjects With Moderate to Severe Plaque Psoriasis
Status: Enrolling
Updated:  1/28/2016
Baker Allergy, Asthma and Dermatology Research Center
mi
from
Lake Oswego, OR
Study to Evaluate Safety and Effectiveness of Oral Apremilast (CC-10004) in Patients With Moderate to Severe Plaque Psoriasis
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Apremilast (CC-10004) in Subjects With Moderate to Severe Plaque Psoriasis
Status: Enrolling
Updated: 1/28/2016
Baker Allergy, Asthma and Dermatology Research Center
mi
from
Lake Oswego, OR
Click here to add this to my saved trials
Study to Evaluate Safety and Effectiveness of Oral Apremilast (CC-10004) in Patients With Moderate to Severe Plaque Psoriasis
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Apremilast (CC-10004) in Subjects With Moderate to Severe Plaque Psoriasis
Status: Enrolling
Updated:  1/28/2016
Oregon Dermatology & Research Center
mi
from
Portland, OR
Study to Evaluate Safety and Effectiveness of Oral Apremilast (CC-10004) in Patients With Moderate to Severe Plaque Psoriasis
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Apremilast (CC-10004) in Subjects With Moderate to Severe Plaque Psoriasis
Status: Enrolling
Updated: 1/28/2016
Oregon Dermatology & Research Center
mi
from
Portland, OR
Click here to add this to my saved trials
Study to Evaluate Safety and Effectiveness of Oral Apremilast (CC-10004) in Patients With Moderate to Severe Plaque Psoriasis
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Apremilast (CC-10004) in Subjects With Moderate to Severe Plaque Psoriasis
Status: Enrolling
Updated:  1/28/2016
Oregon Medical Research Center, PC
mi
from
Portland, OR
Study to Evaluate Safety and Effectiveness of Oral Apremilast (CC-10004) in Patients With Moderate to Severe Plaque Psoriasis
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Apremilast (CC-10004) in Subjects With Moderate to Severe Plaque Psoriasis
Status: Enrolling
Updated: 1/28/2016
Oregon Medical Research Center, PC
mi
from
Portland, OR
Click here to add this to my saved trials
Study to Evaluate Safety and Effectiveness of Oral Apremilast (CC-10004) in Patients With Moderate to Severe Plaque Psoriasis
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Apremilast (CC-10004) in Subjects With Moderate to Severe Plaque Psoriasis
Status: Enrolling
Updated:  1/28/2016
Oregon Health and Science University
mi
from
Portland, OR
Study to Evaluate Safety and Effectiveness of Oral Apremilast (CC-10004) in Patients With Moderate to Severe Plaque Psoriasis
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Apremilast (CC-10004) in Subjects With Moderate to Severe Plaque Psoriasis
Status: Enrolling
Updated: 1/28/2016
Oregon Health and Science University
mi
from
Portland, OR
Click here to add this to my saved trials
Study to Evaluate Safety and Effectiveness of Oral Apremilast (CC-10004) in Patients With Moderate to Severe Plaque Psoriasis
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Apremilast (CC-10004) in Subjects With Moderate to Severe Plaque Psoriasis
Status: Enrolling
Updated:  1/28/2016
University of Pittsburgh
mi
from
Pittsburgh, PA
Study to Evaluate Safety and Effectiveness of Oral Apremilast (CC-10004) in Patients With Moderate to Severe Plaque Psoriasis
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Apremilast (CC-10004) in Subjects With Moderate to Severe Plaque Psoriasis
Status: Enrolling
Updated: 1/28/2016
University of Pittsburgh
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Study to Evaluate Safety and Effectiveness of Oral Apremilast (CC-10004) in Patients With Moderate to Severe Plaque Psoriasis
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Apremilast (CC-10004) in Subjects With Moderate to Severe Plaque Psoriasis
Status: Enrolling
Updated:  1/28/2016
Radiant Research
mi
from
Greer, SC
Study to Evaluate Safety and Effectiveness of Oral Apremilast (CC-10004) in Patients With Moderate to Severe Plaque Psoriasis
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Apremilast (CC-10004) in Subjects With Moderate to Severe Plaque Psoriasis
Status: Enrolling
Updated: 1/28/2016
Radiant Research
mi
from
Greer, SC
Click here to add this to my saved trials
Study to Evaluate Safety and Effectiveness of Oral Apremilast (CC-10004) in Patients With Moderate to Severe Plaque Psoriasis
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Apremilast (CC-10004) in Subjects With Moderate to Severe Plaque Psoriasis
Status: Enrolling
Updated:  1/28/2016
Dermatology Treatment & Research Center, PA
mi
from
Dallas, TX
Study to Evaluate Safety and Effectiveness of Oral Apremilast (CC-10004) in Patients With Moderate to Severe Plaque Psoriasis
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Apremilast (CC-10004) in Subjects With Moderate to Severe Plaque Psoriasis
Status: Enrolling
Updated: 1/28/2016
Dermatology Treatment & Research Center, PA
mi
from
Dallas, TX
Click here to add this to my saved trials
Study to Evaluate Safety and Effectiveness of Oral Apremilast (CC-10004) in Patients With Moderate to Severe Plaque Psoriasis
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Apremilast (CC-10004) in Subjects With Moderate to Severe Plaque Psoriasis
Status: Enrolling
Updated:  1/28/2016
Menter Dermatology Research Institute
mi
from
Dallas, TX
Study to Evaluate Safety and Effectiveness of Oral Apremilast (CC-10004) in Patients With Moderate to Severe Plaque Psoriasis
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Apremilast (CC-10004) in Subjects With Moderate to Severe Plaque Psoriasis
Status: Enrolling
Updated: 1/28/2016
Menter Dermatology Research Institute
mi
from
Dallas, TX
Click here to add this to my saved trials
Study to Evaluate Safety and Effectiveness of Oral Apremilast (CC-10004) in Patients With Moderate to Severe Plaque Psoriasis
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Apremilast (CC-10004) in Subjects With Moderate to Severe Plaque Psoriasis
Status: Enrolling
Updated:  1/28/2016
Center for Clinical Studies
mi
from
Houston, TX
Study to Evaluate Safety and Effectiveness of Oral Apremilast (CC-10004) in Patients With Moderate to Severe Plaque Psoriasis
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Apremilast (CC-10004) in Subjects With Moderate to Severe Plaque Psoriasis
Status: Enrolling
Updated: 1/28/2016
Center for Clinical Studies
mi
from
Houston, TX
Click here to add this to my saved trials
Study to Evaluate Safety and Effectiveness of Oral Apremilast (CC-10004) in Patients With Moderate to Severe Plaque Psoriasis
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Apremilast (CC-10004) in Subjects With Moderate to Severe Plaque Psoriasis
Status: Enrolling
Updated:  1/28/2016
Dermatology Clinical Research Center of San Antonio
mi
from
San Antonio, TX
Study to Evaluate Safety and Effectiveness of Oral Apremilast (CC-10004) in Patients With Moderate to Severe Plaque Psoriasis
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Apremilast (CC-10004) in Subjects With Moderate to Severe Plaque Psoriasis
Status: Enrolling
Updated: 1/28/2016
Dermatology Clinical Research Center of San Antonio
mi
from
San Antonio, TX
Click here to add this to my saved trials
Study to Evaluate Safety and Effectiveness of Oral Apremilast (CC-10004) in Patients With Moderate to Severe Plaque Psoriasis
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Apremilast (CC-10004) in Subjects With Moderate to Severe Plaque Psoriasis
Status: Enrolling
Updated:  1/28/2016
University of Utah School of Medicine
mi
from
Salt Lake City, UT
Study to Evaluate Safety and Effectiveness of Oral Apremilast (CC-10004) in Patients With Moderate to Severe Plaque Psoriasis
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Apremilast (CC-10004) in Subjects With Moderate to Severe Plaque Psoriasis
Status: Enrolling
Updated: 1/28/2016
University of Utah School of Medicine
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Study to Evaluate Safety and Effectiveness of Oral Apremilast (CC-10004) in Patients With Moderate to Severe Plaque Psoriasis
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Apremilast (CC-10004) in Subjects With Moderate to Severe Plaque Psoriasis
Status: Enrolling
Updated:  1/28/2016
St George Dermatology and Skin Cancer Centre
mi
from
Kogarah,
Study to Evaluate Safety and Effectiveness of Oral Apremilast (CC-10004) in Patients With Moderate to Severe Plaque Psoriasis
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Apremilast (CC-10004) in Subjects With Moderate to Severe Plaque Psoriasis
Status: Enrolling
Updated: 1/28/2016
St George Dermatology and Skin Cancer Centre
mi
from
Kogarah,
Click here to add this to my saved trials
A Comparison of DFD01 Spray Versus Comp01 Lotion, Vehicle Spray and Vehicle Lotion in Subjects With Moderate Psoriasis
Status: Enrolling
Updated:  2/8/2016
Academic Dermatology Associates
mi
from
Albuquerque, NM
A Comparison of DFD01 Spray Versus Comp01 Lotion, Vehicle Spray and Vehicle Lotion in Subjects With Moderate Psoriasis
Status: Enrolling
Updated: 2/8/2016
Academic Dermatology Associates
mi
from
Albuquerque, NM
Click here to add this to my saved trials
A Comparison of DFD01 Spray Versus Comp01 Lotion, Vehicle Spray and Vehicle Lotion in Subjects With Moderate Psoriasis
Status: Enrolling
Updated:  2/8/2016
Burke Pharmaceutical Research
mi
from
Hot Springs, AR
A Comparison of DFD01 Spray Versus Comp01 Lotion, Vehicle Spray and Vehicle Lotion in Subjects With Moderate Psoriasis
Status: Enrolling
Updated: 2/8/2016
Burke Pharmaceutical Research
mi
from
Hot Springs, AR
Click here to add this to my saved trials
A Comparison of DFD01 Spray Versus Comp01 Lotion, Vehicle Spray and Vehicle Lotion in Subjects With Moderate Psoriasis
Status: Enrolling
Updated:  2/8/2016
California Dermatology and Clinical Research Institute
mi
from
Encinitas, CA
A Comparison of DFD01 Spray Versus Comp01 Lotion, Vehicle Spray and Vehicle Lotion in Subjects With Moderate Psoriasis
Status: Enrolling
Updated: 2/8/2016
California Dermatology and Clinical Research Institute
mi
from
Encinitas, CA
Click here to add this to my saved trials
A Comparison of DFD01 Spray Versus Comp01 Lotion, Vehicle Spray and Vehicle Lotion in Subjects With Moderate Psoriasis
Status: Enrolling
Updated:  2/8/2016
Carolina Dermatology of Greenville, PA
mi
from
Greenville, SC
A Comparison of DFD01 Spray Versus Comp01 Lotion, Vehicle Spray and Vehicle Lotion in Subjects With Moderate Psoriasis
Status: Enrolling
Updated: 2/8/2016
Carolina Dermatology of Greenville, PA
mi
from
Greenville, SC
Click here to add this to my saved trials
A Comparison of DFD01 Spray Versus Comp01 Lotion, Vehicle Spray and Vehicle Lotion in Subjects With Moderate Psoriasis
Status: Enrolling
Updated:  2/8/2016
Center for Clinical Studies
mi
from
Webster, TX
A Comparison of DFD01 Spray Versus Comp01 Lotion, Vehicle Spray and Vehicle Lotion in Subjects With Moderate Psoriasis
Status: Enrolling
Updated: 2/8/2016
Center for Clinical Studies
mi
from
Webster, TX
Click here to add this to my saved trials
A Comparison of DFD01 Spray Versus Comp01 Lotion, Vehicle Spray and Vehicle Lotion in Subjects With Moderate Psoriasis
Status: Enrolling
Updated:  2/8/2016
Center for Dematology Clinical Research, Inc.
mi
from
Fremont, CA
A Comparison of DFD01 Spray Versus Comp01 Lotion, Vehicle Spray and Vehicle Lotion in Subjects With Moderate Psoriasis
Status: Enrolling
Updated: 2/8/2016
Center for Dematology Clinical Research, Inc.
mi
from
Fremont, CA
Click here to add this to my saved trials
A Comparison of DFD01 Spray Versus Comp01 Lotion, Vehicle Spray and Vehicle Lotion in Subjects With Moderate Psoriasis
Status: Enrolling
Updated:  2/8/2016
Cherry Creek Research, Inc
mi
from
Denver, CO
A Comparison of DFD01 Spray Versus Comp01 Lotion, Vehicle Spray and Vehicle Lotion in Subjects With Moderate Psoriasis
Status: Enrolling
Updated: 2/8/2016
Cherry Creek Research, Inc
mi
from
Denver, CO
Click here to add this to my saved trials
A Comparison of DFD01 Spray Versus Comp01 Lotion, Vehicle Spray and Vehicle Lotion in Subjects With Moderate Psoriasis
Status: Enrolling
Updated:  2/8/2016
Coastal Carolina Research Center
mi
from
Mt. Pleasant, SC
A Comparison of DFD01 Spray Versus Comp01 Lotion, Vehicle Spray and Vehicle Lotion in Subjects With Moderate Psoriasis
Status: Enrolling
Updated: 2/8/2016
Coastal Carolina Research Center
mi
from
Mt. Pleasant, SC
Click here to add this to my saved trials
A Comparison of DFD01 Spray Versus Comp01 Lotion, Vehicle Spray and Vehicle Lotion in Subjects With Moderate Psoriasis
Status: Enrolling
Updated:  2/8/2016
Colorado Medical Research Center
mi
from
Denver, CO
A Comparison of DFD01 Spray Versus Comp01 Lotion, Vehicle Spray and Vehicle Lotion in Subjects With Moderate Psoriasis
Status: Enrolling
Updated: 2/8/2016
Colorado Medical Research Center
mi
from
Denver, CO
Click here to add this to my saved trials
A Comparison of DFD01 Spray Versus Comp01 Lotion, Vehicle Spray and Vehicle Lotion in Subjects With Moderate Psoriasis
Status: Enrolling
Updated:  2/8/2016
Compliant Clinical Research
mi
from
Olathe, KA
A Comparison of DFD01 Spray Versus Comp01 Lotion, Vehicle Spray and Vehicle Lotion in Subjects With Moderate Psoriasis
Status: Enrolling
Updated: 2/8/2016
Compliant Clinical Research
mi
from
Olathe, KA
Click here to add this to my saved trials
A Comparison of DFD01 Spray Versus Comp01 Lotion, Vehicle Spray and Vehicle Lotion in Subjects With Moderate Psoriasis
Status: Enrolling
Updated:  2/8/2016
David Fivenson, MD, PLC
mi
from
Ann Arbor, MI
A Comparison of DFD01 Spray Versus Comp01 Lotion, Vehicle Spray and Vehicle Lotion in Subjects With Moderate Psoriasis
Status: Enrolling
Updated: 2/8/2016
David Fivenson, MD, PLC
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
A Comparison of DFD01 Spray Versus Comp01 Lotion, Vehicle Spray and Vehicle Lotion in Subjects With Moderate Psoriasis
Status: Enrolling
Updated:  2/8/2016
Dermatology Research Center
mi
from
Salt Lake City, UT
A Comparison of DFD01 Spray Versus Comp01 Lotion, Vehicle Spray and Vehicle Lotion in Subjects With Moderate Psoriasis
Status: Enrolling
Updated: 2/8/2016
Dermatology Research Center
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
A Comparison of DFD01 Spray Versus Comp01 Lotion, Vehicle Spray and Vehicle Lotion in Subjects With Moderate Psoriasis
Status: Enrolling
Updated:  2/8/2016
Dermatology Specialists Research
mi
from
Louisville, KY
A Comparison of DFD01 Spray Versus Comp01 Lotion, Vehicle Spray and Vehicle Lotion in Subjects With Moderate Psoriasis
Status: Enrolling
Updated: 2/8/2016
Dermatology Specialists Research
mi
from
Louisville, KY
Click here to add this to my saved trials
A Comparison of DFD01 Spray Versus Comp01 Lotion, Vehicle Spray and Vehicle Lotion in Subjects With Moderate Psoriasis
Status: Enrolling
Updated:  2/8/2016
DermResearch Center of New York Stony Brook Medical Park
mi
from
Stony Brook, NY
A Comparison of DFD01 Spray Versus Comp01 Lotion, Vehicle Spray and Vehicle Lotion in Subjects With Moderate Psoriasis
Status: Enrolling
Updated: 2/8/2016
DermResearch Center of New York Stony Brook Medical Park
mi
from
Stony Brook, NY
Click here to add this to my saved trials
A Comparison of DFD01 Spray Versus Comp01 Lotion, Vehicle Spray and Vehicle Lotion in Subjects With Moderate Psoriasis
Status: Enrolling
Updated:  2/8/2016
DermResearch, Inc.
mi
from
Austin, TX
A Comparison of DFD01 Spray Versus Comp01 Lotion, Vehicle Spray and Vehicle Lotion in Subjects With Moderate Psoriasis
Status: Enrolling
Updated: 2/8/2016
DermResearch, Inc.
mi
from
Austin, TX
Click here to add this to my saved trials
A Comparison of DFD01 Spray Versus Comp01 Lotion, Vehicle Spray and Vehicle Lotion in Subjects With Moderate Psoriasis
Status: Enrolling
Updated:  2/8/2016
Encino Research Center
mi
from
Encino, CA
A Comparison of DFD01 Spray Versus Comp01 Lotion, Vehicle Spray and Vehicle Lotion in Subjects With Moderate Psoriasis
Status: Enrolling
Updated: 2/8/2016
Encino Research Center
mi
from
Encino, CA
Click here to add this to my saved trials